Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

MAP kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MAP3K (3) MAP4K (19) MAPKAPK2 (MK2) (4) MEK (2) AAK1 (1) Apoptosis (3) Aurora Kinase (1) Autophagy (6) Bcr-Abl (2) CaMK (1) CDK (3) COX (1) Cyclin G-associated Kinase (GAK) (1) Enterovirus (1) ERK (2) Ferroptosis (2) LIM Kinase (LIMK) (2) Liposome (1) Microtubule/Tubulin (1) Molecular Glues (1) NF-κB (1) NO Synthase (1) Organoid (2) p38 MAPK (16) PDGFR (1) Phosphodiesterase (PDE) (1) PROTACs (3) Salt-inducible Kinase (SIK) (2) Src (2) TGF-β Receptor (1) ULK (2) Wee1 (1)
By Research Areas:	Cancer (26) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (23) Metabolic Disease (1) Neurological Disease (3)

By Targets:

MAP3K (3)

MAP4K (19)

MAPKAPK2 (MK2) (4)

MEK (2)

AAK1 (1)

Apoptosis (3)

Aurora Kinase (1)

Autophagy (6)

Bcr-Abl (2)

CaMK (1)

CDK (3)

COX (1)

Cyclin G-associated Kinase (GAK) (1)

Enterovirus (1)

ERK (2)

Ferroptosis (2)

LIM Kinase (LIMK) (2)

Liposome (1)

Microtubule/Tubulin (1)

Molecular Glues (1)

NF-κB (1)

NO Synthase (1)

Organoid (2)

p38 MAPK (16)

PDGFR (1)

Phosphodiesterase (PDE) (1)

PROTACs (3)

Salt-inducible Kinase (SIK) (2)

Src (2)

TGF-β Receptor (1)

ULK (2)

Wee1 (1)

By Research Areas:

Cancer (26)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (23)

Metabolic Disease (1)

Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Targets Recommended: MAP3K MAP4K MEK MNK MAPKAPK2 (MK2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-77251

TAK1/MAP4K2 inhibitor 1 1 Publications Verification	MAP4K MAP3K	Cancer
TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) inhibitor, with IC₅₀s of 41.1 nM and 18.2 nM, respectively.

HY-125012

MAP4K4-IN-3 1 Publications Verification	MAP4K	Metabolic Disease
MAP4K4-IN-3 (Compound 17) is a potent and selective *MAP4K4* inhibitor with an IC₅₀ of 14.9 nM in kinase assay, an IC₅₀ of 470 nM in cell assay. Antidiabetic agent .

HY-143212

18:0-22:6 DG 1-Stearoyl-2-docosahexaenoyl-sn-glycerol	Liposome p38 MAPK	Others
18:0-22:6 DG (1-Stearoyl-2-docosahexaenoyl-sn-glycerol) is a diacylglycerol that can bind to RasGRP and modulate **MAP kinases** activation .

HY-122464A

Jasmonic acid (-)-Jasmonic acid	Molecular Glues	Others
Jasmonic acid ((-)-Jasmonic acid) is a plant growth regulator and a derivative of α-Linolenic acid (HY-N0728). Jasmonic acid signaling can also induce the MAP kinase cascade pathway, calcium channel, and many processes that interact with signaling molecules .

HY-152860

Darizmetinib

HRX-0215
p38 MAPK Cancer

Darizmetinib is an inhibitor of mitogen-activated protein kinase kinase (MAP2K) .

Darizmetinib HRX-0215	p38 MAPK	Cancer
Darizmetinib is an inhibitor of mitogen-activated protein kinase kinase (MAP2K) .

HY-145041

HPK1-IN-15	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-15 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-15 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2018049200A1, compound 50) .

HY-145042

HPK1-IN-16	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-16 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-16 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019051199A1, compound 39) .

HY-145044

HPK1-IN-17	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-17 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-17 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019238067A1, compound 73) .

HY-145045

HPK1-IN-18	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-18 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-18 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019238067A1, compound 1) .

HY-112389

*p38 MAP* Kinase Inhibitor III** 1 Publications Verification	p38 MAPK	Inflammation/Immunology
p38 MAP Kinase Inhibitor III (compound 7h) is a p38 MAPK inhibitor with an ₅₀ of 0.9 μM. p38 MAP Kinase Inhibitor III also inhibits IL-1β and TNF-α release with ₅₀ values of 0.37 μM and 0.044 μM, respectively .

HY-143868

HPK1-IN-27	MAP4K	Cancer
HPK1-IN-27 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-27 has the potential for the research of cancer diseases (extracted from patent WO2019016071A1, compound 38) .

HY-143871

HPK1-IN-30	MAP4K	Cancer
HPK1-IN-30 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-30 has the potential for the research of cancer diseases (extracted from patent WO2021175271A1, compound 3) .

HY-N2484

Methylnissolin Astrapterocarpan	PDGFR ERK	Cardiovascular Disease
Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC₅₀ of 10 μM. Methylnissolin inhibits PDGF-BB-induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERIC1/2) mitogen-activated protein (MAP) kinase. Methylnissolin inhibits PDGF-BB-induced vascular smooth muscle cell proliferation by inhibition of the ERK1/2 MAP kinase cascade .

HY-49073

p38 MAP Kinase Inhibitor Ⅵ

p38 MAPK Cancer

p38 MAP Kinase Inhibitor VI (compound c32) is a p38 MAPK inhibitor with an inhibition rate of 24% .

*p38 MAP* Kinase Inhibitor Ⅵ**	p38 MAPK	Cancer
p38 MAP Kinase Inhibitor VI (compound c32) is a p38 MAPK inhibitor with an inhibition rate of 24% .

HY-148061

DB1113	PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK)	Others
DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity .

HY-18306

SB 242235 1 Publications Verification	p38 MAPK Autophagy	Cancer
SB-242235 is a potent and selective p38 MAP kinase inhibitor, with an IC₅₀ of 1.0　μM in primary human chondrocytes .

HY-16715

Acumapimod 1 Publications Verification BCT197	p38 MAPK Autophagy	Inflammation/Immunology
Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC₅₀ of less than 1 μM for p38α.

HY-19562

PF-06260933 1 Publications Verification	MAP4K	Inflammation/Immunology
PF-06260933 is an orally active and highly selective inhibitor of *MAP4K4* with IC₅₀s of 3.7 and 160 nM for kinase and cell, respectively.

HY-145702

MAP855	MEK ERK	Cancer
MAP855 is a highly potent, selective, ATP-competitive and orally active MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC₅₀=3 nM, pERK EC₅₀=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2 .

HY-P3894

*P34cdc2 Kinase* Fragment**	Microtubule/Tubulin	Others
P34cdc2 Kinase Fragment is associated with the completion of DNA replication in yeast mitosis. P34cdc2 Kinase can phosphorylate mitogen-activated protein 2 (MAP2) to regulate microtubules polymerization in Xenopus oocytes meiosis .

HY-12358

*Tpl2 Kinase* Inhibitor 1** 1 Publications Verification	MAP3K p38 MAPK MAPKAPK2 (MK2)	Inflammation/Immunology Cancer
Tpl2 Kinase Inhibitor 1 is a 3-pyridylmethylamino analog, and is a selective Tpl2 inhibitor (IC₅₀=50 nM). Tpl2 consists of COT kinase and *MAP3K8. Tpl2 Kinase* Inhibitor 1 plays an important role in the regulation of the inflammatory response and the progression of some cancers .

HY-10578

PD 169316 10+ Cited Publications	p38 MAPK Autophagy Enterovirus	Cancer
PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor, with IC₅₀ of 89 nM. PD169316 selectively inhibits the kinase activity of the phosphorylated p38 without hindering upstream kinases to phosphorylate p38. PD169316 shows antiviral activity against Enterovirus71. PD169316 shows antiviral activity against Enterovirus71.

HY-139504

Gamcemetinib CC-99677	MAPKAPK2 (MK2)	Inflammation/Immunology
Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC₅₀=156.3 nM) and cell based assays (EC₅₀=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1 .

HY-11087

SD 0006 SD-06	p38 MAPK Autophagy	Inflammation/Immunology
SD 0006 (SD-06) is an orally active, selective, ATP-competitive and potent diaryl pyrazole inhibitor of p38α MAP kinase, with an IC₅₀ of 110 nM for p38α .

HY-10395

PD173955 1 Publications Verification	Bcr-Abl Src	Cancer
PD173955 is an orally active inhibitor of Src (IC₅₀= 22 nM), Yes, Abl, ATP and *MAP* kinases. PD173955 can effectively prevent the mitotic process and has anticancer activity .

HY-106477

Quazinone Ro 13-6438; Ro 13-6438/006	Phosphodiesterase (PDE) MAPKAPK2 (MK2)	Infection
Quazinone is a selective inhibitor of cGMP-inhibited-phosphodiesterase (cGI-PDE, PDE3). Quazinone inhibits the phosphorylation of p42/p44 MAP kinase. Quazinone possesses antimitogenic effect .

HY-112401

*p38 MAP* Kinase Inhibitor IV**	p38 MAPK	Inflammation/Immunology
p38 MAP Kinase Inhibitor IV is a highly specific ATP-competitive p38α MAPK inhibitor with IC₅₀s of 0.13 and 0.55 μM for p38α and p38β MAPK, respectively .

HY-19562A

PF-06260933 hydrochloride	MAP4K	Inflammation/Immunology
PF-06260933 hydrochloride is the hydrochloride form of PF-06260933 (HY-19562). PF-06260933 hydrochloride is an orally active and highly selective inhibitor of *MAP4K4* with IC₅₀s of 3.7 and 160 nM for kinase and cell, respectively .

HY-10295A

SB 202190 hydrochloride Maximum Cited Publications 80 Publications Verification	Organoid p38 MAPK Autophagy Apoptosis	Neurological Disease Cancer
SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC₅₀s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a K_d of 38 nM. SB 202190 hydrochloride has anti-cancer activity . SB202190 hydrochloride induces autophagy .

HY-10295

SB 202190 Maximum Cited Publications 80 Publications Verification	Organoid p38 MAPK Autophagy Apoptosis	Neurological Disease Cancer
SB 202190 is a selective p38 MAP kinase inhibitor with IC₅₀s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a K_d of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .

HY-14305

BMS-582949	p38 MAPK	Inflammation/Immunology
BMS-582949 (compound 7k) is an orally active and highly selective p38α MAP kinase inhibitor, with IC₅₀ values of 13 nM for p38α, and 50 nM for cellular TNFα. BMS-582949 can be used for research on rheumatoid arthritis .

HY-112349

SB 203580 sulfone	p38 MAPK	Inflammation/Immunology
SB 203580 sulfone is an analog of p38 MAP kinase inhibitor SB 203580, which inhibits the IL-1 production in monocytes with an IC₅₀ of 0.2 μM and binds competitively with CSAID binding proteins (CSBP), inhibits it mediated stress response signaling with an IC₅₀ of 0.03 μM .

HY-N0811

Anemarsaponin B	NO Synthase COX NF-κB MEK	Inflammation/Immunology
Anemarsaponin B is a steroidal saponin. Anemarsaponin B decreases the protein and mRNA levels of iNOS and COX-2. Anemarsaponin B reduces the expressions and productions of pro-inflammatory cytokines, including TNF-a and IL-6. Anemarsaponin B inhibits the nuclear translocation of the p65 subunit of NF-κB by blocking the phosphorylation of IκBα. Anemarsaponin B also inhibits the phosphorylation of MAP kinase kinases 3/6 (MKK3/6) and mixed lineage kinase 3 (MLK3). Anti-inflammatory effect .

HY-145036

HPK1-IN-10	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-10 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-10 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 103) .

HY-145037

HPK1-IN-11	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-11 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-11 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 2) .

HY-145038

HPK1-IN-12	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-12 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-12 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 85) .

HY-145039

HPK1-IN-13	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-13 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-13 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 64) .

HY-145040

HPK1-IN-14	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-14 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-14 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 79) .

HY-145035

HPK1-IN-9	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-9 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) .

HY-163429

J-1149	TGF-β Receptor p38 MAPK	Inflammation/Immunology Cancer
J-1149 is a potent ALK5 inhibitor, with an IC₅₀ value of 0.017 μM. J-1149 also shows weak p38α MAP kinase inhibitory activity, with an IC₅₀ value of 0.435 μM. J-1149 can be used for liver fibrosis research .

HY-138568

HPK1-IN-3	MAP4K	Inflammation/Immunology
HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC₅₀ of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC₅₀ of 108 nM in human peripheral blood mononuclear cells (PBMCs) .

HY-114331

DLK-IN-1	MAP3K	Neurological Disease
DLK-IN-1 is a selective, orally active inhibitor of dual leucine zipper kinase (DLK, MAP3K12), with a K_i of 3 nM. DLK-IN-1 retains excellent CNS penetration and is well tolerated following multiple days of dosing at concentrations that exceed those required for DLK inhibition in the brain. DLK-IN-1 has activity in a model of Alzheimer’s Disease.

HY-N7255

Cycloartenol	p38 MAPK Apoptosis	Cancer
Cycloartenol, a phytosterol compound, is one of the key precusor substances for biosynthesis of numerous sterol compounds. Cycloartenol inhibits the migration of glioma cells and suppresses the phosphorylation of the p38 MAP kinase. Cycloartenol has a variety of pharmacological activities such as anti-inflammatory, anti-tumor, antioxidant, antibiosis and anti-alzheimer's disease. Cycloartenol also plays an important role in the process of plant growth and development .

HY-W011428

Olomoucine	CDK	Others
Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC₅₀=7 µM), CDK/p35 kinase (IC₅₀=3 µM) and ERK1/p44 MAP kinase (IC₅₀=25 µM) . Olomoucine regulates cell cycle and shows anti-melanin tumor activity .

HY-148063

DB0614	PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) ULK Wee1 LIM Kinase (LIMK)	Others
DB0614 (Example 21) is a bifunctional compound targeted protein degradation of kinases. DB0614 degrades AAK1, AURKA, BMP2K, CAMKK1, CDK16, CML, CDK6, EIF2AK2, FER, GAK, LCK, LIMK2, MAP3KH, MAPK8, MAPK9, NEK9, PLK4, PTK2B, SIK2, STK17A, STK17B, ULK1, ULK3, and WEE1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity .

HY-148065

FMF-06-098-1	PROTACs	Cancer
FMF-06-098-1 is a multitargeted depressant. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .

HY-107024

Osteogenic Growth Peptide (10-14) OGP(10-14); Historphin	Src	Others
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Src inhibitor .

HY-138742

HPK1-IN-7	MAP4K	Cancer
HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC₅₀=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks